boothcheck doesn't label SRPT overvalued or undervalued and publishes no house fair value, target price, or buy/sell rating. Individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The price is justified by relative-multiple; asset-based/earnings-power land below the price. The report narrative was composed 2026-07-11. The more the price assumes beyond what Sarepta Therapeutics, Inc. has actually delivered, the more has to go right to justify it. Whether that bar is too high is your call, and the full bull and bear cases are in the report.
Derived from Sarepta Therapeutics, Inc.'s SEC EDGAR filings via a reverse-DCF inversion. Last analyzed July 11, 2026.
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.